Centessa Pharma jumps after Eli Lilly agrees to buy co for up to $7.8 billion

Centessa Pharmaceuticals

31/03/2026 12:17

** U.S.-listed shares of Centessa Pharmaceuticals CNTA.O 260y.F rise 45.9% to $40.25 premarket

** Eli Lilly LLY.N to buy the Boston- and London-based drug developer for up to $7.8 billion

** Upfront cash consideration represents an aggregate equity value of about $6.3 billion, with an additional ~$1.5 billion to be contingent on certain milestones, say companies

** Acquisition will expand LLY's neuroscience portfolio and capabilities in sleep medicine

** As of last close, CNTA up 10.3% YTD

(Reporting by Puyaan Singh)

((Puyaan.Singh@thomsonreuters.com;))